Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis [1]

Blood

Volumn 101, Issue 9, 2003, Pages 3749-

  Finazzi, Guido ^a   Ruggeri, Marco ^b   Rodeghiero, Francesco ^b   Barbui, Tiziano ^b  

^a OSPEDALI RIUNITI   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; HYDROXYUREA; WARFARIN; ANAGRELIDE; QUINAZOLINE DERIVATIVE;

ADULT; ARTERY THROMBOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LETTER; LONG TERM CARE; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTHEMIA; TREATMENT OUTCOME; VEIN THROMBOSIS; ADOLESCENT; ANEMIA; BLEEDING; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; COMPARATIVE STUDY; INCIDENCE; MIDDLE AGED; NOTE; RISK; THROMBOPHILIA; THROMBOSIS;

ADOLESCENT; ADULT; ANEMIA; COHORT STUDIES; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; HYDROXYUREA; INCIDENCE; MIDDLE AGED; QUINAZOLINES; RISK; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOPHILIA; THROMBOSIS;

EID: 0037528684     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-01-0135     Document Type: Letter

References (4)

1. Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood. 2001;97:863-866.
2. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332:1132-1136.
3. Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood. 2000;96:4261-4266,
4. 2 production of polymorphonuclear neutrophils from patients with sickle cell anemia. Blood. 2002;99:2297-2303.